Erasca Inc Asset Resilience Ratio
Erasca Inc asset resilience ratio. Erasca Inc (ERAS) has an Asset Resilience Ratio of 51.99% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ERAS days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Erasca Inc (2019–2025)
Asset resilience ratio of Erasca Inc from 2019 to 2025. This chart shows how Erasca Inc's Asset Resilience Ratio has changed over time. Read ERAS total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Erasca Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ERAS asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $226.20 Million | 51.99% |
| Total Liquid Assets | $226.20 Million | 51.99% |
Asset Resilience Insights
- Very High Liquidity: Erasca Inc maintains exceptional liquid asset reserves at 51.99% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Erasca Inc Industry Peers by Asset Resilience Ratio
Compare Erasca Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Erasca Inc Asset Resilience Ratio by Year (2019–2025)
Erasca Inc asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Erasca Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 51.06% | $202.27 Million | $396.15 Million | +5.18pp |
| 2024-12-31 | 45.88% | $230.57 Million | $502.53 Million | -9.59pp |
| 2023-12-31 | 55.47% | $219.28 Million | $395.30 Million | +26.07pp |
| 2022-12-31 | 29.40% | $151.40 Million | $514.91 Million | +18.64pp |
| 2021-12-31 | 10.77% | $53.99 Million | $501.42 Million | -31.95pp |
| 2020-12-31 | 42.72% | $53.33 Million | $124.83 Million | +5.28pp |
| 2019-12-31 | 37.44% | $20.79 Million | $55.51 Million | -- |
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid … Read more